Thelansis

 Hodgkin lymphoma (HL) is a type of cancer affecting white blood cells called B lymphocytes. It is the most common type of lymphoma in young adults. HL is highly treatable, with a cure rate of over 90% for early-stage disease. However, 5-10% of patients will have a disease that is resistant to initial treatment (refractory disease), and 10-30% of patients will relapse after initial treatment. For patients with relapsed or refractory HL, the standard of care is salvage chemotherapy followed by autologous stem cell transplant (ASCT). However, half of patients will still have disease progression after ASCT. Relapse following ASCT is associated with a very poor prognosis, with a median survival of only 26 months.   Thelansis’s “Relapsed or Refractory Classical Hodgkin’s Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landsca...

 Hodgkin lymphoma (HL) is a B-cell malignancy representing approximately 1 in 10 lymphomas diagnosed in the United States annually. Most patients with HL can be cured with chemotherapy; however, 5-10% will have the refractory disease to frontline therapy, and 10-30% will relapse. For those with relapsed or refractory (r/r) HL, salvage chemotherapy followed by autologous stem cell transplant (ASCT) is standard of care, but half of the patients will subsequently have disease progression. Relapse following ASCT has been associated with exceedingly poor prognosis with a median survival of only 26 months. ·        Hodgkin lymphoma (HL) is a B-cell malignancy, representing approximately 10% of all lymphomas seen in the United States, with an incidence of over 8500 cases per year. ·        Most patients with either limited or advanced stage cHL can be cured with chemotherapy; however, 5–10% will have the refractory disease to...